Profund Advisors’s Vanda Pharmaceuticals VNDA Stock Holding History

Profund Advisors’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$196K	Sell	32,103 -9,126	-22%	-$59.6K	0.01%	1098
2026 Q1	$285K	Buy	+41,229	New	+$318K	0.01%	774
2023 Q3	–	Sell	-42,644	Closed	-$281K	–	1087
2023 Q2	$281K	Sell	42,644 -3,041	-7%	-$19.5K	0.02%	764
2023 Q1	$310K	Buy	+45,685	New	+$321K	0.02%	701
2021 Q3	–	Sell	-10,855	Closed	-$231K	–	1449
2021 Q2	$231K	Buy	+10,855	New	+$194K	0.01%	1264
2019 Q1	–	Sell	-15,756	Closed	-$412K	–	1244
2018 Q4	$412K	Sell	15,756 -9,030	-36%	-$212K	0.03%	564
2018 Q3	$569K	Buy	+24,786	New	+$506K	0.02%	705

Other funds holding VNDA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Profund Advisors's VNDA Position: Q2 2026 in Review

Profund Advisors reduced its Vanda Pharmaceuticals (VNDA) stake by 22% in Q2 2026, selling an estimated $59.6K and leaving 32,103 shares worth $196K. The position accounts for 0.01% of the portfolio, ranked #1098.

Profund Advisors first reported a position in VNDA in Q3 2018 and has held it in 7 quarters since. The position peaked at $569K in Q3 2018. 173 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

Profund Advisors held 32,103 shares of Vanda Pharmaceuticals worth $196K as of Q2 2026.
Profund Advisors sold 9,126 Vanda Pharmaceuticals shares in Q2 2026, an estimated $59.6K.
Vanda Pharmaceuticals made up 0.01% of Profund Advisors's portfolio in Q2 2026, its #1098 holding.
Profund Advisors first reported a position in Vanda Pharmaceuticals in Q3 2018 and has held it in 7 quarters since.
Profund Advisors's Vanda Pharmaceuticals position peaked at $569K in Q3 2018.
173 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.